Quantcast

BioTime Announces Collaboration With the International Longevity Center on Regenerative Medicine

October 13, 2008

BioTime, Inc. (OTCBB:BTIM) and the International Longevity Center-USA today announced a collaboration aimed at research, education and advocacy for regenerative medicine and its application in aging. Founded by President and CEO, Robert N. Butler, M.D. in 1990, the International Longevity Center is a non-profit international research, policy, and education organization formed to educate individuals on how to live longer and better, and advise society on how to maximize the benefits of technology, such as the emerging field of regenerative medicine for today’s age boom. BioTime is a biotechnology company developing human embryonic stem cell research and induced pluripotent stem cell (“iPS”) products from human embryonic stem cells and iPS technology potentially useful in restoring function in tissues afflicted with age-related degenerative disease.

“The technology to transform aged human cells back to embryonic stem cells and then into the diverse cells types of the body has profound implications for the future of an aging population,” said Michael D. West, Ph.D., CEO of BioTime, Inc. “Since the discovery of human embryonic stem cells has unlocked the potential to produce all of the cell types of the human body, there is a significant novel opportunity to develop a large number of products for an array of age-related degenerative diseases. It is critical to expedite the process of education of the public, policy makers, and members of the pharmaceutical industry to this important trend, and that is the purpose of our collaboration.”

Dr. Butler, who recently joined the BioTime board of directors, is considered a foremost authority on aging. He was the first director of the National Institute on Aging of the National Institutes of Health, he founded the first department of geriatrics in a U.S. medical school at The Mount Sinai Medical Center, and he is the Pulitzer Prize-winning author of Why Survive, as well as more than 300 scientific papers and books. Dr. Butler is widely credited with coining the term “ageism” and educating the country about the need for innovative therapies for Alzheimer’s disease. In his recently published book, The Longevity Revolution, he asserts that regenerative medicine, based on embryonic stem cells, could conceivably treat Alzheimer’s as well as other dreaded diseases.

“The discovery of iPS technology has potentially broken the ethical logjam by providing a path to making embryonic stem cells identical to a patient without using embryos,” said Dr. Butler. “We look forward to collaborating with BioTime to communicate through policy reports, symposia, and the media the potential of these new technologies in regenerative medicine for an aging population.”

About The International Longevity Center

The International Longevity Center-USA (ILC-USA) is a not-for-profit, nonpartisan research, education, and policy organization whose mission is to help individuals and societies address longevity and population aging in positive and productive ways, and to highlight older people’s productivity and contributions to their families and society as a whole.

The organization is part of a multinational research and education consortium, which includes centers in the United States, Japan, Great Britain, France, the Dominican Republic, India, South Africa, and Argentina. These centers work both autonomously and collaboratively to study how greater life expectancy and increased proportions of older people impact nations around the world. ILC publications are available online at www.ilcusa.org.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime’s lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at www.biotimeinc.com. Hextend(R), PentaLyte(R), HetaCool(R), Embryomics(TM), ESpy(TM), and ESpan(TM) are trademarks of BioTime, Inc.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,”"believes,”"plans,”"anticipates,”"expects,”"estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company’s business, particularly those mentioned in the cautionary statements found in the company’s Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0.




comments powered by Disqus